Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients…
– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc.…
Novartis said Tuesday that the USFDA marked its investigational sickle cell drug crizanlizumab for Priority Review, which could be the first monoclonal antibody targeting the P-selectin mediated multi-cellular adhesion in sickle cell disease.
Continued growth in 2019 marked by new HD-X product launch, acquisition of the leading neurofilament light (Nf-L) antibody supplier, new…
City of Hope’s Arthur D. Riggs, Ph.D., a world-renowned expert in molecular biology and diabetes, and his wife, Jane, established…
ALACHUA, Fla.–(BUSINESS WIRE)–CTD Holdings, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease…
Taris Bio has dosed the first patient in a test of its investigational product TAR-200 combined with Bristol-Myers Squibb’s Opdivo.
Biomarck Pharmaceuticals has improved the Overall Response Rate (ORR) in the BIO-11006/SOC group compared to standard of care alone at 3 months in the Phase 2 study in NSCLC, which compares standard of care alone, to SOC plus BIO-11006 in 60 patients with stage 4.
Trovagene has started erolling patients for its second phase study of onvansertib plus FOLFIRI and Avastin (bevacizumab) for second-line treatment of patients with metastatic colorectal cancer (mCRC) with a KRAS mutation.
Catalyst adopts unified platform approach to immediately offer impactful and competitive services for biopharmaceutical companies New full service offerings adopt…